Trials / Recruiting
RecruitingNCT07213973
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Povorcitinib | Oral; Tablet |
Timeline
- Start date
- 2026-02-02
- Primary completion
- 2028-03-25
- Completion
- 2028-03-25
- First posted
- 2025-10-09
- Last updated
- 2026-04-06
Locations
27 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07213973. Inclusion in this directory is not an endorsement.